Entera Bio (ENTX) Cost of Revenue (2019 - 2025)

Entera Bio (ENTX) has reported Cost of Revenue for 6 consecutive years, with $42000.0 the latest figure, recorded in Q1 2025.

• Quarterly Cost of Revenue changed N/A year-over-year to $42000.0 in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $42000.0 (down 75.58% YoY) and the FY2025 annual result came in at $42000.0, down 75.58% from the prior year.
• Cost of Revenue slipped to $42000.0 in Q1 2025 per ENTX's latest filing, from $82000.0 in the prior quarter.
• Over the last five years, Cost of Revenue for ENTX reached as high as $136000.0 in Q4 2021 and fell as low as $6000.0 in Q3 2022.
• A 4-year average of $57333.3 and a median of $51000.0 in 2022 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2021 — Cost of Revenue soared 219.35% — and 2022, when it plunged 94.12%.
• Year by year, Cost of Revenue stood at $136000.0 in 2021, then tumbled by 94.12% to $8000.0 in 2022, then soared by 925.0% to $82000.0 in 2024, then plunged by 48.78% to $42000.0 in 2025.
• According to Business Quant data, Cost of Revenue over the past three periods registered $42000.0, $82000.0, and $42000.0 for Q1 2025, Q4 2024, and Q3 2024 respectively.